Merck & Co., Inc.'s JANUVIA(TM) Approved in the European Union for the Treatment of Type 2 Diabetes

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- JANUVIA™ (sitagliptin1), Merck & Co., Inc.'s once-a-day oral treatment for patients with type 2 diabetes, has been granted a license from the European Commission. JANUVIA now becomes the first and only medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which enhance the body’s own ability to lower blood sugar when it is elevated, to be adopted by the European Commission.

Back to news